Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 31, 2004. The report primarily details a share repurchase transaction and updates regarding directors' interests in company shares held through employee benefit plans.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to the share buyback:
- Shares Purchased: 450,000 Ordinary Shares
- Purchase Price: 1,142.57 pence per Share
- Treasury Shares Held: 39,318,000 (post-transaction)
- Shares in Issue: 5,894,897,623 (excluding treasury shares)
Material Changes
The primary material change reported is the reduction of outstanding shares through a treasury buyback executed on August 27, 2004, authorized by shareholders at the May 17, 2004 Annual General Meeting. Additionally, minor changes in directors' interests were noted due to movements in the GlaxoSmithKline US Retirement Savings Plan and transfers from the GlaxoSmithKline Employee Trust to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the 450,000 share repurchase against the reported price of 1,142.57 pence.
- Confirm the updated total share count (5,894,897,623) and treasury holdings (39,318,000) in subsequent filings.
- Review the impact of the US Retirement Savings Plan movement on the specific holdings of directors Dr. J P Garnier and Dr. T Yamada.
- Check for any additional share repurchase authorizations or limits remaining from the May 2004 shareholder approval.